Developer docs
API playgroundTry for free, no card

Search company profiles

Aragen Bioscience

Full company profile

uuid0009cdy

Namestring
Aragen Bioscience
Legal namestring
Aragen Life Sciences Ltd. and Aragen Biosciences Inc.
Websiteurl
aragenbio.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Aragen Bioscience is a privately-held contract research, development, and manufacturing organization (CRDMO) specializing in biologics, operating as a division of Aragen Life Sciences. Founded in 2006 and headquartered in Morgan Hill, California, the company provides integrated services spanning cell line development, process development, bioproduction, analytical characterization, antibody discovery, and GLP-compliant preclinical efficacy testing. Its proprietary technology platforms — CHOMax™ (launched January 2026) and RapTr2022 (launched August 2023) — center on CHO (Chinese Hamster Ovary) cell line development using CHO-DG44 and CHO-GS lines with proprietary expression vectors, refined across more than 200 programs. The platforms target DNA-to-IND-enabling clinical supply timelines of approximately 10 months, with reported titers of 8 g/L at clonal stage and up to 27 g/L after process optimization, offered on a royalty-free basis to sponsors.

The company serves a diversified customer base of 400+ clients across biotech, biosimilars, animal health, and government/academic research segments, including 7 of the top 10 global pharmaceutical companies. Revenue is generated through project-based fee-for-service contracts and integrated managed-service programs spanning cell line development through GMP manufacturing. Distribution is direct enterprise sales with no channel or reseller model; go-to-market includes active participation in major industry conferences (BIO, PEGS Boston, CPHI, IPF Summit, DCAT) and a content-driven marketing approach.

Aragen operates a dual-hub model with R&D and early development at its Morgan Hill campus and biologics manufacturing at a new Bengaluru, India facility built through a $30M investment in wholly-owned subsidiary Aragen Biologics Pvt Ltd, operationalized in March 2024 with single-use bioreactor capacity from 50L to 2000L and annual capacity of 60–70 batches at 2KL scale. The organization employs approximately 5,000 people globally, including 450+ PhD-qualified scientists across six sites, and has completed 222 regulatory and client audits and 86+ global regulatory filings. The group is led by Manni Kantipudi (CEO, Aragen Life Sciences) and Subodh Deshmukh (CEO, Aragen Biologics).

Short descriptiontext

Aragen Bioscience is a private CRDMO providing integrated biologics development and manufacturing services, from cell line development through GMP production, using proprietary CHO-based platforms. It serves 400+ biotech, pharma, biosimilar, animal health, and academic clients from California R&D and Bengaluru manufacturing sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMorgan Hill, United States
HQ citystring
Morgan Hill
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, biologics development, cell line development, GMP manufacturing, preclinical efficacy testing
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research, Development, and Manufacturing Services (Biologics CRO/CRDMO)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service contract research including cell line development, process development, analytical services, and preclinical efficacy testing. Revenue generated through project-based contracts with milestones and deliverables.

aragenbio.com
2Contract Manufacturing Services
TypeProfessional Services
Description

GMP manufacturing services for biologics including monoclonal antibodies, therapeutic proteins, and fusion proteins. Manufacturing capacity spans from 50L to 2000L single-use bioreactors.

aragenbio.com
3Integrated Gene-to-GMP Programs
TypeManaged Services
Description

Comprehensive integrated programs from DNA through IND-enabling clinical supply, combining development and manufacturing services under unified project management.

aragenbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1RapTr
Description

Accelerated biologics development platform launched in 2023, designed to reduce development timelines by 33%

aragenbio.com
+1 more record
Core offering1 text field

Aragen Bioscience is a contract research, development, and manufacturing organization (CRDMO) providing biologics services from cell line development through GMP manufacturing, plus preclinical efficacy testing across multiple therapeutic areas. Its offerings include CHO-based cell line development (CHOMax™ and RapTr2022 platforms), protein expression and purification, analytical and bioanalytical services, process development, GMP drug substance manufacturing (50L to 2,000L single-use bioreactors), antibody discovery, and preclinical in vivo efficacy studies in fibrosis, oncology, immunology, infectious, and respiratory diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • DNA to IND-enabling clinical supply in ~10 months for standard IgG mAbs
+4 more records
Product and service1 record
1Cell Line Development
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Ongoing strategic collaboration for manufacturing Renaissance Pharma's FDA Fast Track designated monoclonal antibody Daretabart (anti-GD2 for high-risk neuroblastoma). Aragen developed cell line and initial process at Morgan Hill, with GMP manufacturing transitioning to Bengaluru facility.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-11
Description

Successful validation of Getinge's Single-Use Production Reactors (SUPR) for large-scale recombinant antibody production. Aragen uses Getinge's 50L and 250L SUPRs at Morgan Hill facility for preclinical and toxicology production. Getinge benefits from customer validation data for their SUPR platform.

3FAR Biotech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-26
Description

Collaboration to advance preclinical programs in neurodegeneration. Aragen deploys its integrated drug discovery platform to help FAR Biotech advance its small molecule program. FAR Biotech provides AI-driven computational drug discovery capabilities with novel molecules for hard-to-drug targets.

aragenbio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lonza is the largest global biologics CDMO offering mammalian cell line development, process development, and large-scale GMP manufacturing of mAbs and recombinant proteins — directly overlapping with Aragen's CHOMax and GMP manufacturing services for the same sponsor base.

TypeDirect peer
Description

AGC Biologics is a mid-tier global biologics CDMO offering mammalian cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins, comparable in scale and service scope to Aragen.

TypeBroad incumbent
Description

Charles River is a large preclinical CRO/CDMO with biologics cell line development, manufacturing, and preclinical efficacy testing services spanning discovery through GMP — relevant to Aragen's preclinical and biologics services portfolio.

4KBI Biologics
TypeDirect peer
Description

KBI Biologics is a mid-size CDMO providing mammalian cell line development, process development, analytical services, and GMP manufacturing of mAbs and recombinant proteins — a comparable integrated biologics services provider.

TypeDirect peer
Description

Rentschler is a privately held European biologics CDMO offering cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins, overlapping directly with Aragen's integrated gene-to-GMP biologics platform.

TypeDirect peer
Description

WuXi Biologics is a leading biologics CRDMO offering cell line development, process development, and GMP manufacturing of mAbs, bispecifics, and recombinant proteins with a global dual-hub model similar to Aragen's California/India footprint.

TypeDirect peer
Description

Catalent is a global CDMO with biologics cell line, process development, and GMP manufacturing services for mAbs and recombinant proteins, directly competing with Aragen for biotech and pharma integrated development programs.

TypeDirect peer
Description

Samsung Biologics operates very large-scale mammalian GMP manufacturing (multi-KL bioreactors) for mAbs and recombinant proteins, plus integrated development services, making it a direct competitor for sponsors seeking gene-to-commercial biologics CDMO capacity.

TypeDirect peer
Description

Fujifilm Diosynth is a major CDMO offering mammalian cell line development, process development, and large-scale GMP manufacturing of biologics — a direct competitor in Aragen's CHO-based integrated services segment.

10Boehringer Ingelheim BioXcellence
TypeDirect peer
Description

BioXcellence is Boehringer Ingelheim's contract manufacturing arm offering process development and large-scale GMP manufacturing of mAbs and recombinant proteins, competing for the same biopharma and biotech sponsor base as Aragen.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aragen Bioscience

Contract Research, Development, and Manufacturing Services (Biologics CRO/CRDMO)aragenbio.com

Aragen Bioscience is a private CRDMO providing integrated biologics development and manufacturing services, from cell line development through GMP production, using proprietary CHO-based platforms. It serves 400+ biotech, pharma, biosimilar, animal health, and academic clients from California R&D and Bengaluru manufacturing sites.

What Aragen Bioscience does

Aragen Bioscience is a privately-held contract research, development, and manufacturing organization (CRDMO) specializing in biologics, operating as a division of Aragen Life Sciences. Founded in 2006 and headquartered in Morgan Hill, California, the company provides integrated services spanning cell line development, process development, bioproduction, analytical characterization, antibody discovery, and GLP-compliant preclinical efficacy testing. Its proprietary technology platforms — CHOMax™ (launched January 2026) and RapTr2022 (launched August 2023) — center on CHO (Chinese Hamster Ovary) cell line development using CHO-DG44 and CHO-GS lines with proprietary expression vectors, refined across more than 200 programs. The platforms target DNA-to-IND-enabling clinical supply timelines of approximately 10 months, with reported titers of 8 g/L at clonal stage and up to 27 g/L after process optimization, offered on a royalty-free basis to sponsors.

The company serves a diversified customer base of 400+ clients across biotech, biosimilars, animal health, and government/academic research segments, including 7 of the top 10 global pharmaceutical companies. Revenue is generated through project-based fee-for-service contracts and integrated managed-service programs spanning cell line development through GMP manufacturing. Distribution is direct enterprise sales with no channel or reseller model; go-to-market includes active participation in major industry conferences (BIO, PEGS Boston, CPHI, IPF Summit, DCAT) and a content-driven marketing approach.

Aragen operates a dual-hub model with R&D and early development at its Morgan Hill campus and biologics manufacturing at a new Bengaluru, India facility built through a $30M investment in wholly-owned subsidiary Aragen Biologics Pvt Ltd, operationalized in March 2024 with single-use bioreactor capacity from 50L to 2000L and annual capacity of 60–70 batches at 2KL scale. The organization employs approximately 5,000 people globally, including 450+ PhD-qualified scientists across six sites, and has completed 222 regulatory and client audits and 86+ global regulatory filings. The group is led by Manni Kantipudi (CEO, Aragen Life Sciences) and Subodh Deshmukh (CEO, Aragen Biologics).

Aragen Bioscience firmographics

Firmographics
Name
Aragen Bioscience
Legal name
Aragen Life Sciences Ltd. and Aragen Biosciences Inc.
Website
https://aragenbio.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Aragen Bioscience is a private CRDMO providing integrated biologics development and manufacturing services, from cell line development through GMP production, using proprietary CHO-based platforms. It serves 400+ biotech, pharma, biosimilar, animal health, and academic clients from California R&D and Bengaluru manufacturing sites.
Ownership category
akta.pro rank

Aragen Bioscience industry classification

Industry
Product category
Contract Research, Development, and Manufacturing Services (Biologics CRO/CRDMO)
NAICS
Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Contract research services
  • Biologics development
  • Cell line development
  • GMP manufacturing
  • Preclinical efficacy testing

Where Aragen Bioscience is headquartered

Location

Headquarters

HQ city
Morgan Hill
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aragen Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services: Fee-for-service contract research including cell line development, process development, analytical services, and preclinical efficacy testing. Revenue generated through project-based contracts with milestones and deliverables.
  2. Contract Manufacturing Services: GMP manufacturing services for biologics including monoclonal antibodies, therapeutic proteins, and fusion proteins. Manufacturing capacity spans from 50L to 2000L single-use bioreactors.
  3. Integrated Gene-to-GMP Programs: Comprehensive integrated programs from DNA through IND-enabling clinical supply, combining development and manufacturing services under unified project management.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Aragen Bioscience product offering

Product offering

Core offering

Aragen Bioscience is a contract research, development, and manufacturing organization (CRDMO) providing biologics services from cell line development through GMP manufacturing, plus preclinical efficacy testing across multiple therapeutic areas. Its offerings include CHO-based cell line development (CHOMax™ and RapTr2022 platforms), protein expression and purification, analytical and bioanalytical services, process development, GMP drug substance manufacturing (50L to 2,000L single-use bioreactors), antibody discovery, and preclinical in vivo efficacy studies in fibrosis, oncology, immunology, infectious, and respiratory diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • RapTr: Accelerated biologics development platform launched in 2023, designed to reduce development timelines by 33%
  • CHOMax

Products and services

  • Cell Line Development

Quantifiable outcome

  • DNA to IND-enabling clinical supply in ~10 months for standard IgG mAbs
  • +4 more outcomes

Companies that use Aragen Bioscience

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles5 records

Aragen Bioscience technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Aragen Bioscience partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Renaissance PharmacoreStrategic or Co-development Partner · 2 June 2026Ongoing strategic collaboration for manufacturing Renaissance Pharma's FDA Fast Track designated monoclonal antibody Daretabart (anti-GD2 for high-risk neuroblastoma). Aragen developed cell line and initial process at Morgan Hill, with GMP manufacturing transitioning to Bengaluru facility.
  • GetingecoreTechnology or Integration · 11 June 2024Successful validation of Getinge's Single-Use Production Reactors (SUPR) for large-scale recombinant antibody production. Aragen uses Getinge's 50L and 250L SUPRs at Morgan Hill facility for preclinical and toxicology production. Getinge benefits from customer validation data for their SUPR platform.
  • FAR BiotechcoreStrategic or Co-development Partner · 26 May 2023Collaboration to advance preclinical programs in neurodegeneration. Aragen deploys its integrated drug discovery platform to help FAR Biotech advance its small molecule program. FAR Biotech provides AI-driven computational drug discovery capabilities with novel molecules for hard-to-drug targets.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Aragen Bioscience competitors and assessment

Company assessment

Direct peers

  • Lonza Biologics: Lonza is the largest global biologics CDMO offering mammalian cell line development, process development, and large-scale GMP manufacturing of mAbs and recombinant proteins — directly overlapping with Aragen's CHOMax and GMP manufacturing services for the same sponsor base.
  • AGC Biologics: AGC Biologics is a mid-tier global biologics CDMO offering mammalian cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins, comparable in scale and service scope to Aragen.
  • KBI Biologics: KBI Biologics is a mid-size CDMO providing mammalian cell line development, process development, analytical services, and GMP manufacturing of mAbs and recombinant proteins — a comparable integrated biologics services provider.
  • Rentschler Biopharma: Rentschler is a privately held European biologics CDMO offering cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins, overlapping directly with Aragen's integrated gene-to-GMP biologics platform.
  • WuXi Biologics: WuXi Biologics is a leading biologics CRDMO offering cell line development, process development, and GMP manufacturing of mAbs, bispecifics, and recombinant proteins with a global dual-hub model similar to Aragen's California/India footprint.
  • Catalent (Novo Holdings): Catalent is a global CDMO with biologics cell line, process development, and GMP manufacturing services for mAbs and recombinant proteins, directly competing with Aragen for biotech and pharma integrated development programs.
  • Samsung Biologics: Samsung Biologics operates very large-scale mammalian GMP manufacturing (multi-KL bioreactors) for mAbs and recombinant proteins, plus integrated development services, making it a direct competitor for sponsors seeking gene-to-commercial biologics CDMO capacity.
  • Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth is a major CDMO offering mammalian cell line development, process development, and large-scale GMP manufacturing of biologics — a direct competitor in Aragen's CHO-based integrated services segment.
  • Boehringer Ingelheim BioXcellence: BioXcellence is Boehringer Ingelheim's contract manufacturing arm offering process development and large-scale GMP manufacturing of mAbs and recombinant proteins, competing for the same biopharma and biotech sponsor base as Aragen.

Broad incumbents

  • Charles River Laboratories: Charles River is a large preclinical CRO/CDMO with biologics cell line development, manufacturing, and preclinical efficacy testing services spanning discovery through GMP — relevant to Aragen's preclinical and biologics services portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Aragen Bioscience social profiles

Digital presence

Aragen Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aragen Bioscience leadership team

Management profile

Number of profiles

Profiles12 records

Aragen Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aragen Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aragen Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aragen Bioscience

What does Aragen Bioscience do?

Aragen Bioscience is a contract research, development, and manufacturing organization (CRDMO) providing biologics services from cell line development through GMP manufacturing, plus preclinical efficacy testing across multiple therapeutic areas. Its offerings include CHO-based cell line development (CHOMax™ and RapTr2022 platforms), protein expression and purification, analytical and bioanalytical services, process development, GMP drug substance manufacturing (50L to 2,000L single-use bioreactors), antibody discovery, and preclinical in vivo efficacy studies in fibrosis, oncology, immunology, infectious, and respiratory diseases.

Is Aragen Bioscience a public or private company?

Aragen Bioscience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Aragen Bioscience founded?

Aragen Bioscience was founded in 2006. It employs 1,001 to 5,000 people.

Where is Aragen Bioscience based?

Aragen Bioscience is headquartered in Morgan Hill, United States, in the North America region.

How does Aragen Bioscience make money?

Three revenue lines are on record. Contract Research Services are the primary driver. The others are contract Manufacturing Services and integrated Gene-to-GMP Programs.

Who are Aragen Bioscience's main competitors?

Direct peers on record are Lonza Biologics, AGC Biologics, KBI Biologics, Rentschler Biopharma, WuXi Biologics, Catalent (Novo Holdings), Samsung Biologics, Fujifilm Diosynth Biotechnologies and Boehringer Ingelheim BioXcellence. Charles River Laboratories is listed as a broad incumbent.

Does Aragen Bioscience have an API?

No public API is recorded for Aragen Bioscience.

What industry is Aragen Bioscience in?

Aragen Bioscience's product category is Contract Research, Development, and Manufacturing Services (Biologics CRO/CRDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioProcess InternationalIndia Targets $150B Bioeconomy With CDMO GrowthIndia is pursuing a $150 billion bioeconomy target by 2025 through its National Biotechnology Development Strategy, which aims to position the country as a global biomanufacturing hub. Leading this expansion are domestic Contract Development and Manufacturing Organizations (CDMOs) such as Syngene International, Aurigene Pharmaceutical Services, Aragen Biologics, and Enzene Biosciences, who are actively investing in new biologics manufacturing facilities and expanding their capabilities.NatureForging robust partnerships in biologics developmentAragen Bioscience, a California-based biologics development company, offers end-to-end services for monoclonal antibodies and other biologics, including cell-line development platforms. The company reports over 200 client partnerships and four marketed products, with a goal to accelerate process-development timelines to IND submission.GlobeNewswireAvid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial ManufacturingAvid Bioservices and Aragen Bioscience announced a co-marketing agreement to offer integrated cell line and process development services. The non-exclusive deal combines Aragen's cell line expertise with Avid's upstream/downstream and analytical services to accelerate CGMP bulk drug substance delivery. The companies aim to reduce timelines and improve efficiencies for biotech and pharma clients.PrwebAragen Bioscience Expands RapTr Cell Line Development ServicesAragen Bioscience expanded its RapTr cell line development services to include CHO-GS cell lines, announced at the Bioprocess International West Conference in San Francisco. The company's royalty-free, fee-for-service approach eliminates the need for third-party cell licensing agreements.PR NewswireGORE™ Protein Capture Device Drives Timeline Reduction For CROAragen Bioscience Inc. is presenting at the 13th Annual PEGS conference about their antibody purification platform that utilizes W.L. Gore's new GORE™ Protein Capture Device, which has reduced their antibody processing turnaround time by 2-3 days. The device uses an ePTFE membrane composite that provides high binding capacity at short residence times, potentially eliminating a downstream concentration step. W.L. Gore & Associates is a global materials science company headquartered in Delaware with approximately 10,000 associates and over $3 billion in annual revenues.GlobeNewswireAragen Bioscience, Inc. and Transposagen Biopharmaceuticals, Inc. Partner to Launch FUT8 Knockout CHO DG44 Cell Line Development ServicesAragen Bioscience and Transposagen partnered to develop a FUT8 knockout CHO DG44 cell line, which produces afucosylated proteins with increased ADCC activity. The company now offers protein expression and cell line development services for research, with GMP manufacturing services expected in the second half of 2015.